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1. Introduction
Malonyl-CoA decarboxylase (E.C.4.1.1.9) deﬁciency (MLYCDD,
OMIM 248360) is a rare autosomal recessive inborn error of metabo-
lism MLYCD is encoded by a MLYCD gene located on chromosome
16q23.3 and consists of 5 exons [1,2]. The expression of the protein is
highest in the cardiac muscle, followed by the skeletal muscle, brain,
small intestine, liver, pancreas and kidney [1–3]. The substrate for
MLYCD is malonyl-CoA, which has been recognized as a key player in
fatty acid synthesis and oxidation in relation to its dual function: 1) as
an intermediate in fatty acid biosynthesis (the formation of malonyl-
CoA by acetyl-CoA carboxylase is the ﬁrst step in fatty acid biosynth-
esis); and 2) as a regulatory eﬀector of fatty acid oxidation through
inhibition of carnitine palmitoyl transferase 1 (CPT1) [4,5]. CPT1 exists
in 3 isoforms – CPT1A, expressed in the liver [6]; CPT1B, expressed
predominantly in the muscular/cardiac tissue [6]; and CPT1C, found
recently in brain [3]. It has been suggested that malonyl-CoA diﬀer-
entially inhibits these isoforms. CPT1B (expressed predominantly in
muscle tissues, where the synthesis of fatty acids is negligible) is 100-
fold more sensitive to malonyl-CoA concentration [7–10]. These ﬁnd-
ings argue for predominantly regulatory rather than synthetic role of
the malonyl-CoA in the skeletal and heart muscle - slight alterations in
malonyl-CoA concentration linked to loss of MLYCD activity may have
profound eﬀects on substrate consumption and energy supply in heart
and muscle and probably can account for the phenotypic similarities of
mitochondrial fatty acid oxidation disorders seen in individuals with
MLYCDD. Additionally, accumulation of cytoplasmic malonyl-CoA in-
hibits long-chain acylcarnitine acetyltansferases, resulting in impaired
fatty acid uptake and beta oxidation in both mitochondria and
peroxisomes [11,12].
The diagnosis of malonic aciduria is based on detection of elevated
levels of malonylcarnitine (C3DC) in blood acylcarnitine proﬁles
[13,14]. Urine organic acid analysis shows high levels of malonic acid.
In some patients, this is accompanied by mild elevations of methyl-
malonic acid, especially during the initial presentation, which may
resemble combined malonic and methylmalonic aciduria, due to mu-
tations in the ACSF3 gene.
In some cases, ketotic dicarboxylic aciduria can be detected by urine
organic acid analysis, a ﬁnding not typical for most fatty acid oxidation
disorders [15]. The diagnosis can be conﬁrmed by molecular testing or
detection of reduced enzyme activity in ﬁbroblasts.
Individuals with MLYCDD present with a variable phenotype which
includes developmental delay, seizures, hypotonia, metabolic acidosis,
hypoglycemia, ketosis and cardiomyopathy. Developmental delay is the
most prominent feature, and cardiomyopathy is the leading cause of
morbidity and mortality. Brain abnormalities characterized by mal-
formation in cortical development and white matter involvement have
been reported in some patients [16–18].
If not detected by newborn screening, most cases of MLYCDD pre-
sent with metabolic decompensation characterized by severe metabolic
acidosis and hypoglycemia, associated with poor prognosis. As a result
of expanded newborn screening, more patients with MLYCDD have
been identiﬁed prior to the onset of symptoms, allowing for early in-
itiation of treatment and potential prevention of complications such as
hypoglycemia, cognitive impairment and cardiomyopathy.
Currently, there are no speciﬁc treatment guidelines for MLYCDD.
Similar to fatty acid oxidation disorders, a high carbohydrate and low-
fat diet has been suggested [2,13,14,19] and medications such as ACE
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inhibitors and beta-blockers have been used for treatment of cardio-
myopathy. In addition, carnitine supplementation may be useful to
correct secondary carnitine deﬁciency and to potentially improve car-
diomyopathy and muscle weakness. Since its ﬁrst description in 1984,
at least 49 patients with MLYCDD have been reported in the literature,
mostly as single case reports. Therefore, not much is known about the
natural history, eﬀect of treatment, beneﬁt of interventions before the
onset of symptoms, long term outcomes and genotype-phenotype cor-
relation.
In this case series we report the clinical, biochemical, molecular and
long-term follow-up, including a systematic review of brain MRI ﬁnd-
ings, in eight previously unreported cases with MLYCDD and update on
one previously published patient [15]. We provide information about
dietary management, long term outcomes and expand on the knowl-
edge regarding the molecular defects associated with this disorder.
2. Methods
This study is a multi-site collaboration between metabolic centers at
CHOC Children's Hospital (4 patients), Children's National Medical
Center (1 patient), University of Missouri (2 patients), Saint Peter's
University Hospital (1 patient) and Children's Hospital of Wisconsin (1
patient). CHOC Children's and Mayo Clinic functioned as the co-
ordinating investigation sites. IRB approval (CHOC IRB # 180423) was
obtained and collaborating institutions signed a letter of agreement to
share their patient's information. All patients had biochemical diagnosis
of MLYCDD. Enzyme activity in ﬁbroblasts (5 patients) was performed
under research protocol using a modiﬁcation of the method of Scholte
[20]. Mutation analysis by Sanger sequencing and deletion analysis by
MLPA were performed by routine clinical testing [21,22]. In silico
analysis of the missense mutations and the eﬀect of splice site altera-
tions was performed utilizing Alamut Visual software (Alamut Visual
version 2.11 -Interactive Biosoftware, Rouen, France). This package
includes the predictive algorithms Mutation taster, SIFT, Polyphen-2
and Align GVGD. The splice site variants were evaluated by 4 diﬀerent
programs (MaxEntScan, NNSPLICE, GeneSplicer and SpliceSiteFinder-
like). In addition, minor allele frequency (MAF, when available) and
conservation of particular amino acid residue in comparison with or-
thologues were also taken into account. Retrospective chart review of
the patients was performed. De-identiﬁed data was collected through a
standardized form by collaborating Institutions at participating sites.
Patient data included demographics, family history, and detailed in-
formation about clinical / biochemical presentation, treatment and
long-term outcomes. Additionally, available brain MRI images (n= 5)
and reports (n=2) were reviewed by the same pediatric neurologist.
Newborn screening (NBS) and conﬁrmatory testing were performed as
mandated by the State where each patient was born. Data regarding
cut-oﬀ values and secondary markers reﬂect those used at the time of
NBS sample collection. Participating institutions provided nutritional
treatment information, and all data was reviewed by the same meta-
bolic dietitian. Longitudinal laboratory data obtained after treatment
initiation was analyzed in the 4 patients that were followed at the same
Institution, using the same laboratory. Only data obtained in ambula-
tory setting, while patients were not acutely ill was included. One way
Anova was used to determine statistically signiﬁcant diﬀerences be-
tween the C3DC means of the diﬀerent patients and Pearson correlation
coeﬃcient was used to assess correlation between the C3DC and free
carnitine values.
3. Results
Table 1 summarizes the initial presentation and diagnostic evalua-
tion of each patient. Four out of 9 patients had neonatal presentation
which included hypoglycemia, metabolic acidosis, respiratory distress,
hypotonia and seizures. The remaining patients were asymptomatic at
the time of diagnosis. Patient 1 was born before expanded newborn Ta
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2
screening (NBS) was available. All patients who had NBS testing had
elevated C3DC, while C3DC/C10 ratio was used as a secondary marker
by some centers. The state of California (CA) was not using secondary
markers for MLYCDD at the time patients 2, 3 and 9 were born; the
values reﬂected on the table were calculated retrospectively using the
raw data from the NBS report. Based on those calculations, patients 2, 3
and 9 would have been positive for the secondary marker as well. In
contrast, patient 5 was born after CA NBS program had implemented
C3DC/C10 ratio as secondary marker, and his result was below the cut-
oﬀ of 5.00 established at the time. Therefore, he was not ﬂagged by the
NBS program, which at the time only ﬂagged patients who had eleva-
tions in both primary and secondary markers for MLYCDD, and was
diagnosed at 6months of age after presenting with respiratory distress
and metabolic acidosis secondary to cardiomyopathy.
Conﬁrmatory testing was available for 5 out of the 7 patients de-
tected by NBS. All of them had elevated C3DC and/or abnormal urine
organic acids, diagnostic of MLYCDD. Free carnitine levels tended to be
low, being below the normal range in 2 of the patients. Four out of the 9
patients had enzymatic analysis in skin ﬁbroblasts with extremely low
enzyme levels.
Almost all types of molecular changes were observed in this cohort.
Even though consanguinity was only reported in one family, seven out
of nine patients had homozygous mutations. Most of the mutations
were large deletions including the entire exon, or splice site variants
leading to a frame shift and termination codon downstream. Two of the
variants were previously described. Patient one has a large homozygous
deletion including 5′ UTR and parts of exon one. However, the
boundaries of this deletion were not identiﬁed by long range PCR [15].
Both parents were carriers as identiﬁed by MLPA analysis. The homo-
zygous mutation in patient two was also previously described [1], this
deletion leads to frameshift and stop codon downstream
[c.640_641+ 2del; p.(Glu214Glyfs*2)]. The rest of the variants were
novel. Deletion of the entire exon 5 was the most frequently en-
countered alteration, found in three individuals including two siblings –
patients 5 and 9. A duplication of 13 nucleotides was observed in pa-
tient seven [(c.22_34dup, p.(Arg12Leufs*200))] leading to frameshift
and stop codon further downstream. In this patient, another variant was
found at splice position c.799-3C>G in IVS3 potentially leading to loss
of an acceptor splice site as predicted by the splice site algorithms.
Another deletion (c.641+ 4_641+ 7del) in IVS2 is also predicted to
alter donor splice site. Three missense variants were identiﬁed in this
study. The c.365T>C (p.Leu122Pro) variant has not been previously
observed, and it aﬀects a highly conserved amino acid (up to C. elegans,
considering 12 species). All used predictor algorithms identiﬁed the
variant as potentially damaging or disease causing (SIFT score 0; Mu-
tationTaster – disease causing; Polyphne-2 score 0.999; and Align
GVGD – C25). The other two variants (c.1125G>T, p.Trp384Cys and
c.929G>C, p.Arg31Pro) are known validated dbSNP variants.
c.929G>C has MAF of 0.001 and 0 homozygotes. All four algorithms
predict damaging or disease causing eﬀect (SIFT - 0.01; MutationTaster
– disease causing; Polyphne-2 -1.0; and Align GVGD – C35) and the
amino acid at that position is conserved to Tetraodon (12 species
considered). This variant has been reported twice in ClinVar
(RCV000764082.1 and RCV000482691.1) and classiﬁed as variant of
uncertain signiﬁcance (VUS). In gnomAD (2.1) overall MAF was
0.0016% and in NFE – 0.0035%. The variant c.1152G>T
(p.Trp384Cys) is known to dbSNP (rs1177070767). It aﬀects a highly
conserved amino acid (down to Tetraodon, considering 12 species). All
four algorithms predict damaging or disease causing eﬀect (SIFT - 0.03;
MutationTaster – disease causing; Polyphne-2 -1.0; and Align GVGD –
C25).
Table 2 summarizes the patient outcomes at the time of their last
evaluation. One patient died (patient 9) of cardiac failure at 9months.
The remaining 8 patients have a median age of 6.5 y (ranged from 1.3
to 14). Only patient 9 had severe failure to thrive.
Routine follow-up over the years, clearly demonstrated that there is
some degree of neurodevelopmental disability in patients with
MLYCDD. Most patients had hypotonia that was frequently associated
with gross motor delays. In addition, most patients had speech and ﬁne
motor delays as well as microcephaly. Intellectual disabilities were
detected in most school aged children.
Three patients in our cohort had seizures. Patient 1 presented with
seizures on day of life 4 possibly related to hypoglycemic episode. After
the correction of the glucose levels he was treated with phenobarbital,
phenytoin and lorazepam which were discontinued over time. Patient 6
presented with seizures at 6months of age. Initial EEG showed inter-
mittent focal slowing and occasional potentially epileptiform dis-
charges. He was not treated with anti-seizure medications and repeat
EEG at 9months of age was normal. Patient 9 was diagnosed with
seizures at 4months of age. His EEG showed mild-to-moderate en-
cephalopathic trace with no epileptiform discharges. He was initially
started on fosphenytoin and later switched to levetiracetam until the
time of his death.
Seven out of 9 patients had a brain MRI, and 4 of them had ab-
normal ﬁndings, including T2 hyperintensities in periventricular white
matter and basal ganglia (Fig. 1).
Patient 5, who was not detected by NBS, presented with dilated
cardiomyopathy. All other patients had routine echocardiograms that
lead to the detection of dilated cardiomyopathy in 4 additional patients
and left ventricular non-compaction in one. In most cases, cardiomyo-
pathies improved or resolved with speciﬁc treatment.
Care of children with MLYCDD required several hospitalizations for
initial evaluations and treatment, acute metabolic decompensations
(acidosis/hypoglycemia), prevention of metabolic crisis during inter-
current illness and/or management of cardiomyopathy. Seven out of
the 9 patients had a total of 23 admissions with an average of 28
hospital-days per admission. Hospital treatment included high glucose
infusion (10% dextrose) and carnitine (50–300mg/kg/day), as well as
management of cardiomyopathy and the intercurrent illness.
It has been recommended that dietary management for MLYCDD
patients mimics that of patients with long-chain fatty acid oxidation
disorders such as VLCAD [14]. Therefore, our patients were treated
with modiﬁed diets to restrict the amount of long -chain fats and sup-
plemented with MCT. Various modalities were used by the diﬀerent
centers.
Table 3 summarizes the treatment during the ﬁrst 6 months of age,
before the introduction of solid foods. Five out of 9 patients were
prescribed a special medical formula restricted in long-chain fats, with
high MCT content, with or without the use of glucose polymers or ad-
ditional oil to meet caloric and essential fatty acids (EFA) requirements.
In 3 patients breast milk was used in combination with MCT and/or
other formulas, and only 1 patient was exclusively breast fed. Four out
of 9 patients required tube feedings, due to poor muscle tone.
Nutritional analysis shows that total fat as a percentage of total
calories was mildly restricted from 22% to 36% in 4 patients, while the
remaining 5 met the DRI requirements for age (40–55%). The intake of
long-chain fat as percentage of total calories was restricted in 8 out of
the 9 patients. Three of them (patients 6, 8 and 9) received<10%
while the remainder received 14–23%. Accordingly, the percentage of
calories provided as MCT ranged from 14 to 38%. Only the patient who
was exclusively breast fed had no long-chain fat restriction or MCT
supplementation. No essential fatty acid deﬁciencies were reported.
Table 4 summarizes treatment at the time of last evaluation. Patient
9 was not included in this table as he died at 9months of age. All pa-
tients were prescribed a diet restricted in long chain fats with MCT
supplementation. For all patients total fat intake was close to the DRI
for age. Out of the 3 patients that required G-tube feedings, only patient
5 was still using it.
All patients, including patient 1 who was not following dietary
treatment initially, were restricted in long chain fats ranging from 8 to
18% total calories, with exception of patient 5 who was following a
very restricted long chain fat intake. MCT supplementation ranged from
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15 to 26% of the total calories, with exception of patient 3 who was
prescribed 13% but was unable to follow recommendations and her
MCT intake was only 2% of total calories.
In order to assess if long term biochemical data correlated with
clinical outcomes, we analyzed the available laboratory data obtained
after treatment initiation in the 4 patients that were followed at the
same Institution, using the same laboratory. C3DC levels tended to be
higher (up to 8.66 μMol) during illness. Therefore, only data obtained
in ambulatory setting, while patients were not acutely ill was included.
Unfortunately, urine organic acids or MMA levels in blood were not
routinely followed. Liver enzymes and CK remained within normal
limits. C3DC levels varied in the same patient over time and among the
diﬀerent patients (Table 5). Patient 2 had the lowest mean C3DC levels
(1.31 μMol) and has a milder clinical course, with no cardiomyopathy
or brain MRI abnormalities. Statistical analysis showed that his levels
were signiﬁcantly diﬀerent from those of patient 5 and 9, who had a
more severe clinical course (Fig. 2a). While the above could suggest a
Fig. 1. MRI of the brain, axial cuts. Patient 1: At 13 years of age. 1a: T2: basal ganglia hyperintensities. 1b: T2: white matter hyperintensities. Patient 3: At 9 years of
age. 3a: T2: periventricular white matter and bilateral basal ganglia hyperintensities. 3b: T1: corresponding basal ganglia hypointensities. Patient 5: At 6 years of age.
5a: T2: bilateral symmetric basal ganglia hyperintensities. 5b:T2: periventricular white matter hyperintensities.
Table 3
Treatment during the ﬁrst 6months of age, before the introduction of solid
foods.
Nutritional source Tube
feedings
Total fat (%
of total
calories)
Long chain
fats (% of
total
calories)
MCT (% of
total
calories)
1 BM N 55 52.2 3.8
2 P+PL N 34 15.0 19.0
3 P+PL G-tube 36 14.0 22.0
4 P N 49 23.0 25.0
5 BM+MCT G-tube 40 15.6 24.7
6 M+PL+MCT+O G-tube 22 7.7 14.3
7 E+BM+O N 50 20.0 30.0
8 BM+MCT N 30 8.0 22.0
9 E NG-tube 45 7.0 38.0
BM: Breastmilk. PL: Polycose ®. P: Pregestimil ®. E: Enfaport ®. M: Monogen ®.
O: walnut, saﬄower or ﬂaxseed oil to provide EFAs.
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correlation between C3DC levels and disease severity, levels of C3DC in
patient 3, who has same mutations and similar severe clinical course as
patients 5 and 9, were not signiﬁcantly diﬀerent from patient 2. To
assess for the possibility that C3DC levels could be inﬂuenced by free
carnitine, we compared all free carnitine values (n=87) with the C3DC
levels that were obtained at the same time. We found that there was a
weak but signiﬁcant correlation between these 2 parameters (r2 0.134,
p < 0.0005) (Fig. 2b).
4. Discussion
MLYCDD is a severe and rare inborn error of metabolism.
Table 4
Dietary treatment at the time of last evaluation.
Age Tube feedings Total fat (% of total calories) Long chain fats (% of total calories) Supplemental MCT (% of total calories) Supplemental MCT (g/kg/day)
1 14 y N 30.0 15.0 15.0 0.7
2 10 y N 30.0 10.0 20.0 1.5
3 9 y N 20.0 18.0 2 a 1.5
4 7 y N 25.0 10.0 15.0 0.6
5 6 y G-tube 31.0 4.1 26.5 2–2.5
6 5 y N 37.5 11.5 26.0 2.3
7 28m N 35.0 14.0 21.0 NA
8 16m N 30.0 8.0 22.0 2.3
Patient 9 not included in this table as he died at 9months of age.
a Prescribed MCT but patient was not compliant. Sources of MCT included: Liquigen ®, Monogen ®, MCT oil Nestle ®.
Table 5
Longitudinal C3DC levels.
Patient Average SD SEM Max MIN N
2 1.31 0.65 0.09 2.98 0.33 47
3 2.01 1.07 0.26 4.03 0.58 17
5 3.77 1.74 0.33 7.98 1.49 28
9 2.59 0.50 0.10 3.66 1.97 7
SD: standard deviation. SEM: standard error of mean. MAX: maximum level.
MIN: minimum level. N: number of values measured.
Fig. 2. a) Mean C3DC values on treatment. b) Linear regression analysis of C3DC levels relative to free carnitine levels. N= 87.
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Implementation of NBS programs has allowed for early identiﬁcation
and reporting of more patients, however, birth prevalence is still very
low.
Our ﬁndings signiﬁcantly expand the number of reported cases and
molecular spectrum of MLYCDD. Additionally, we provide important
information about long term manifestations and response to treatment.
While NBS can detect most MLYCDD cases, newborns can be
symptomatic prior to the availability of NBS results, high level of sus-
picion is required if clinical presentation is suggestive (hypoglycemia,
respiratory distress etc.).
All patients who had NBS testing had elevated C3DC. A secondary
marker, C3DC/C10 was used by some programs and appeared to be
useful, except for patient 5 who had borderline low levels.
Most recently, the Collaborative Laboratory Integrated Reports
(CLIR) post-analytical interpretive tools have been available to la-
boratories and clinicians to assist in the interpretation of initial NBS
results [23]. The clinical utility of these tools is based on the replace-
ment of traditional cutoﬀ values with covariate-adjusted reference and
disease ranges and the integration of informative markers with all
possible permutation of calculated ratios. Single condition tools in-
tegrate all relevant results into a single score [23]. To evaluate if a tool
for the condition under study would have been useful in our population,
we entered NBS values for patients 2, 3, 5 and 9, for whom all required
information, including birthweight and hours of age at specimen col-
lection, was available. For patients 2 and 3 the tool predicted the di-
agnosis of MLYCD to be very likely, while the diagnosis was predicted
as likely for patients 5 and 9. Interestingly, these 2 patients were sib-
lings, had the lowest C3DC values, and one of them (patient 5) was not
detected by the NBS program as his C3DC/C10 ratio was below the
chosen cutoﬀ value. The use of CLIR could have prompted a referral and
conﬁrmatory testing in this case. Therefore, the routine use of this tool
may facilitate the correct diagnosis of MLYCDD even when NBS results
are deemed inconclusive by a conventional approach. This is particu-
larly important considering that patients 5 and 9 had severe disease
manifestations including death, and initial C3DC levels do not appear to
correlate with disease severity or outcome.
Most of our families were of Mexican descent, seven families had
homozygous mutations however, consanguinity was only reported in
one family. All but two mutations have not been previously reported.
No correlation between mutation and enzyme activity could be es-
tablished given that the measured enzyme activity was signiﬁcantly low
in all patients and it is diﬃcult to make comparisons regarding residual
enzyme activity. In addition to the typical clinical presentation, bio-
chemical abnormalities and, in some cases, the determined low enzyme
activity, the predicted in silico outcome of the identiﬁed variants argue
that they are disease causing mutations. Since crystal structure of
malonyl-CoA decarboxylase has not been reported, in vitro studies are
needed to further determine the eﬀect on molecular level.
Patients 3, 5 and 9 have the same homozygous mutations, however
their clinical presentations and outcomes are diﬀerent. Patients 5 and 9
are siblings, and while the latter was picked up by NBS and had the
beneﬁt of early treatment, he died of severe cardiomyopathy before the
ﬁrst year of life. On the other hand, his brother started treatment late,
after presenting with cardiomyopathy at 6months of age. He is cur-
rently 6 years old, has stable cardiomyopathy and mild neurodevelop-
mental delays. Unlike patients 5 and 9, patient 3 had a severe neonatal
presentation however; she is also doing well at 9 years of age with
stable cardiomyopathy and mild delays. It is possible that additional
factors such as intercurrent illnesses, or a second underlying disorder in
consanguineous families, may play a role in the severity of the clinical
presentations and outcomes.
As previously reported, most common manifestations were related
to cardiomyopathy and neurological involvement. However, clinical
expression was variable, ranging from asymptomatic to severe cardio-
myopathy and death. It is possible that some of the observed clinical
heterogeneity might be due to variable expression of the MLYCD gene
in diﬀerent cell types [24,25].
Neurodevelopmental delay was the most prevalent ﬁnding in our
patient cohort, followed by microcephaly and hypotonia. While sei-
zures are an expected complication in patients with MLYCDD [24], only
3 patients in our cohort had a history of seizures. Based on our data and
previous reports [5,15,16,26,27] there doesn't seem to be a speciﬁc
seizure type or EEG pattern. Of note, the 3 patients who had seizures
presented during infancy and the 2 who are still alive have been seizure
free and oﬀ antiepileptic treatment at ages 5 and 14 years. As in the
case of patient 1, the seizure episode could have been related to severe
hypoglycemia.
The etiology of neurodevelopmental delays or seizures in MLYCDD
is not clear, although it is possible that hypoglycemia could be a pre-
disposing factor.
Consistent with previous reports [16], brain MRI abnormalities
were found in 4 out of 7 patients. The most common abnormalities
observed were T2 hyperintensities in the white matter and basal ganglia
(Fig. 1), which are not uncommon manifestations of organic acidemias
[28,29].
Interestingly, diﬀerent from previous reports, brain atrophy was not
observed in our patient cohort [5,12,17,24,30]. In most of the reported
patients, atrophy was detected in infancy; therefore, the lack of brain
atrophy in our cohort cannot be attributed to their age. Early delayed
myelination observed in patients 1 and 7 is likely to be related to factors
other than MLYCDD given that they resolved over time.
The etiology of MRI abnormalities in patients with MLYCDD is un-
clear but could be related to episodes of acute metabolic decom-
pensation or hypoxia related to cardiac insuﬃciency. Another me-
chanism could be the persistently elevated levels of malonyl-CoA in the
brain, with secondary inhibition of CPT-1 expressed in the brain [3].
One out of the 9 patients in our series died, which is comparable to
the outcome reported by Celato et al. in larger cohort [31]. The cause of
death in our patient, as well as in those previously reported, was sec-
ondary to severe cardiomyopathy. He also had severe feeding intoler-
ance and failure to thrive. NG tube feedings were attempted during the
last month of life. It is possible that a more aggressive nutritional
management could have improved the outcome.
The most common cardiac abnormality in our cohort was dilated
cardiomyopathy, while previous reports have described both, hyper-
trophic [1,15,32,33] as well as dilated cardiomyopathies
[14,26,34,35]. Patient 7, had left ventricular non-compaction (LVNC);
making him the third reported MLCYD patient with this ﬁnding
[36,37]. Therefore, LVNC together with hypertrophic and dilated car-
diomyopathy are common manifestations in patients with MLYCDD.
The cause of the cardiac ﬁndings in MLCYDD, is not fully under-
stood. Dilated cardiomyopathy is commonly seen in patients with long
chain fatty acid oxidation disorders (FAOD) and could be expected
based on the inhibitory eﬀect of malonyl-CoA on CPT1. However, LVNC
or hypertrophy cardiomyopathies are not common in FAOD and could
be related to other mechanisms, including mitochondrial dysfunction
due to accumulation of potentially toxic organic acids [4,36,38].
Of note, most of our patients were asymptomatic at the time of di-
agnosis and cardiomyopathy was identiﬁed during routine echo-
cardiogram. All patients with cardiomyopathy, with exception of the
patient who died, exhibited improvement in cardiac function after in-
itiation of treatment with cardiac medications and/or dietary mod-
iﬁcations (Table 2).
Due to the known inhibition of mitochondrial FAO by malonyl-CoA,
historically patients with MLYCDD have been treated with a fat re-
stricted diet [13,14,35]. Currently there are no speciﬁc dietary guide-
lines for MLYCDD, therefore dietary recommendations for VLCAD are
usually followed. According to GMDI Management Guidelines [39]
patients should receive the dietary reference intake (DRI) for age for
total fat, however the composition of fat intake should be modiﬁed by
restricting long chain fats and adding MCT. All our patients followed
similar dietary recommendations with some variations (Tables 3 and 4).
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Due to the limited number of reported patients at the time, Patient
1, who has a severe mutation and had neonatal presentation, was
started on modiﬁed diet supplemented with MCT oil at 6 months of age.
The combination of dietary treatment and treatment with angiotensin-
converting enzyme (ACE) inhibitor led to resolution of cardiomyopathy
(EF>30%; normal for age<30%) and the ACE inhibitor was dis-
continued. Similarly, patient 5 did not start dietary treatment until
6 months of age. Interestingly, long term clinical course for these 2
patients is not diﬀerent from the rest of our cohort. Patient 9 died of
severe cardiomyopathy despite receiving the most signiﬁcant long-
chain fat restriction and higher amount of MCT. This dietary inter-
vention does not appear to have contributed to his death, given that
patients 6 and 8 were following similar restriction in long chain-fat and
are currently doing well.
Based on our ﬁndings, current treatment modalities appear to be
beneﬁcial to treat / prevent acute metabolic crises. However, as pre-
viously reported, cardiomyopathy cannot be prevented by fasting pre-
cautions or dietary interventions alone. However, a combination of a
long chain fat restriction, MCT supplementation and ACE inhibitor
therapy improves cardiac outcome [36]. Considering that patient 9 died
despite receiving the above interventions, it is possible that MLYCDD
patients with severe cardiomyopathy may beneﬁt from new therapies
that appear to be beneﬁcial for patients with long chain FAOD and
severe cardiac disease [40].
Longitudinal biochemical markers were reviewed in 4 patients.
C3DC values varied over time and although increases were seen at the
time of acute illness, statistical analysis did not support a correlation
between C3DC mean values and prognosis. It is possible that our ana-
lysis may be inﬂuenced by the diﬀerent number of samples available for
each subject and/or the carnitine levels. Despite the variations noted
over time, we observed that C3DC values tended to be higher when
patients were on MCT formulas and appeared to decrease with age,
irrespective of dietary intervention or compliance. It is possible that
measuring malonic acid levels in blood or urine in these patients could
have been useful to monitor treatment or predict disease severity.
5. Conclusions
Our ﬁndings signiﬁcantly expand the number of reported cases and
molecular spectrum of MLYCDD. While NBS can detect most MLYCDD
cases, clinicians must be aware of this condition as newborns can be
symptomatic prior to the availability of NBS results. Early im-
plementation of a diet restricted in long-chain fat and high MCT in
combination with cardiac medications improve the outcome of cardiac
disease, however, these interventions may not completely prevent other
disease complications such as neurodevelopmental disabilities and
brain MRI abnormalities.
Based on our experience, monitoring for CNS disease (neurodeve-
lopmental testing/brain MRI) and cardiomyopathy (serial echocardio-
grams) should be implemented as standard of care for this disorder.
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